Co-Authors
This is a "connection" page, showing publications co-authored by Georg Behrens and Metodi Stankov.
Connection Strength
2.267
-
Humoral and Cellular Immune Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Human Coronaviruses After Single BNT162b2 Vaccination. Clin Infect Dis. 2021 12 06; 73(11):2000-2008.
Score: 0.983
-
SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination. Lancet. 2021 09 18; 398(10305):1041-1042.
Score: 0.241
-
Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis. EBioMedicine. 2021 Aug; 70:103524.
Score: 0.240
-
Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat Med. 2021 09; 27(9):1525-1529.
Score: 0.239
-
Strategic Anti-SARS-CoV-2 Serology Testing in a Low Prevalence Setting: The COVID-19 Contact (CoCo) Study in Healthcare Professionals. Infect Dis Ther. 2020 Dec; 9(4):837-849.
Score: 0.225
-
Perceived versus proven SARS-CoV-2-specific immune responses in health-care professionals. Infection. 2020 Aug; 48(4):631-634.
Score: 0.222
-
SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. Cell Rep. 2021 07 20; 36(3):109415.
Score: 0.060
-
COVID-19 immune signatures reveal stable antiviral TÂ cell function despite declining humoral responses. Immunity. 2021 02 09; 54(2):340-354.e6.
Score: 0.058